Premium
Hypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen
Author(s) -
Monnier Laurie,
Touboul Emmanuel,
Durdux Catherine,
Lang Philippe,
St Guily Jean Lacau,
Huguet Florence
Publication year - 2013
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23219
Subject(s) - medicine , regimen , chemoradiotherapy , radiation therapy , head and neck cancer , oncology , chemotherapy , progression free survival , head and neck , head and neck squamous cell carcinoma , surgery
Background Standard treatment for unresectable advanced head and neck squamous cell carcinoma is chemoradiotherapy, which can be toxic, particularly among patients with coexisting medical conditions. We report our experience with the hypofractionated radiotherapy regimen Irradiation HypoFractionnée 2 Séances Quotidiennes (IHF2SQ). Methods We retrospectively reviewed 78 patients treated with the IHF2SQ regimen. Radiotherapy was administrated as 2 fractions of 3 Gy per day (days 1 and 3), during the first, third, fifth, and seventh week of treatment with concurrent platinum‐based chemotherapy. Results Tolerance was excellent. Forty‐one patients had complete or partial response. Median overall survival (OS) was 12.9 months and median progression‐free survival (PFS) was 10.3 months. One‐year OS, specific survival (SS), and PFS were 58%, 71%, 51.5%, respectively. Independent predictive factors increasing the PFS were response to chemoradiotherapy, male sex, and laryngeal tumor location. Conclusions This regimen is an alternative to conventional chemoradiotherapy with good response rates and acceptable toxicity for selected patients. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1683–1688, 2013